The concept of Antibody-Drug Conjugates (ADCs) as simple "chemo attached to an antibody" is a significant oversimplification. True efficacy is highly dependent on complex factors like the linker's cleavage properties within the acidic tumor microenvironment, creating a "bystander effect" that is crucial to their function.
The significant stomatitis (mouth sores) associated with the ADC Dato-DXD requires proactive management. Beyond standard steroid rinses and ice chips, a new refrigerated 'chemo mouthpiece' device is being adopted in clinical practice as an innovative, non-pharmacologic tool to prevent this severe side effect.
Clinicians are moving beyond strict immunohistochemistry cutoffs for treatment decisions. Tumors with low estrogen receptor expression (ER-low, <10%) are often considered not to be primarily estrogen-driven and are treated with immunotherapy-based regimens standard for triple-negative disease, reflecting a shift toward biologically-informed therapy.
Despite the trial protocol specifying day 1 and day 8 dosing for the ADC Sacituzumab Govitecan (SG), community practitioners are frequently using a day 1 and day 15 schedule. This real-world adaptation is happening anecdotally to manage toxicity, with formal prospective studies still ongoing to validate the approach.
Recent trial data shows that patients with somatic BRCA1/2 mutations (found only in the tumor, not inherited) can achieve significant responses to PARP inhibitors. This finding supports routine tumor genomic testing to identify more candidates for this targeted therapy beyond just those with germline mutations.
Advances like immunotherapy and Antibody-Drug Conjugates (ADCs) in early-stage Triple-Negative Breast Cancer (TNBC) are so effective that fewer patients are relapsing. This success paradoxically makes it harder to enroll patients in trials for metastatic disease, shifting the trial population toward those with de novo metastatic cancer.
For de novo metastatic, PD-L1 positive TNBC patients with a BRCA mutation, experts prefer an ADC with immunotherapy over a PARP inhibitor. This choice is driven by the potential for longer-lasting responses with the ADC/IO combination, even though PARP inhibitors directly target the underlying genetic mutation.
Retrospective data shows that using one Antibody-Drug Conjugate (ADC) after another, particularly those with the same class of payload like TOP1 inhibitors, results in a low response rate of 10-20%. This creates a significant unmet need and a major clinical challenge for patients who progress on a first-line ADC.